Related Experiment Video
Updated: Apr 17, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and
Marjet J A M Braamskamp1, D Meeike Kusters, Hans J Avis
1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands, j.a.braamskamp@amc.uva.nl.
Insights
Young adults with familial hypercholesterolemia (FH) showed good adherence and tolerability to statin therapy initiated in childhood. Most patients continued treatment for ten years with mild side effects, indicating long-term treatment success.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Familial hypercholesterolemia (FH) management aims to prevent premature atherosclerosis using statins.
- While statins are effective and generally safe in adults, non-adherence is a significant challenge.
Purpose of the Study:
- To assess the long-term tolerability and adherence to statin therapy in young adult patients with FH.
- To evaluate outcomes 10 years after initiating statin treatment during childhood.
Main Methods:
- A questionnaire was administered to 214 young adult FH patients who started statin therapy at least 10 years prior.
- Adherence was defined as taking 80% or more of prescribed medication.
- Tolerability was assessed by the percentage of patients discontinuing therapy due to side effects.
Main Results:
- Follow-up was achieved in 205 patients (age 18-30 years).
- 19.5% reported mild side effects (muscle/GI complaints); only 1.5% discontinued therapy.
- 82.4% remained on statins, with 78.7% demonstrating good adherence; no serious adverse events occurred.
Conclusions:
- Childhood-initiated statin therapy in FH patients is well-tolerated and demonstrates good long-term adherence.
- Mild side effects were reported by a minority, with most patients continuing treatment successfully for a decade.
Background:
Statins are currently the preferred pharmacological therapy in individuals with familial hypercholesterolemia (FH) with the aim to prevent premature atherosclerosis. In adults, these agents have been proven to be safe and well tolerated; however, non-adherence is a significant clinical issue.
Objectives:
In this study, we evaluated tolerability and adherence to statin therapy in young adult FH patients 10 years after this was initiated in their childhood.
Methods:
A questionnaire including items on medical history, adherence and reasons for discontinuation was sent to 214 young adult FH patients that initiated statin therapy at least 10 years ago. Tolerability was defined as 100% minus the percentage of patients that discontinued statin therapy due to side effects. Adherence was defined as the extent to which patients took their medication as prescribed by their physician. We labelled patients adherent if they took 80% or more of their pills in the month preceding our assessment.
Results:
Follow-up was successful in 205 (95.8%) subjects (age 18-30 years). A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. Three patients (1.5%) discontinued statin therapy because of side effects. Rhadbomyolysis or other serious adverse events were not reported. In fact, 169 (82.4%) of 205 patients remained on statin treatment and 78.7% (148 out of 188) were adherent. None of the patient characteristics were significantly associated with adherence.
Conclusions:
Individuals with FH who started statin therapy in childhood demonstrated good adherence during ten years of treatment. Furthermore, statin therapy was well tolerated; only a small minority discontinued therapy because of side effects and the side effects that were reported were mild in nature.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenomics: Identification of New Drug Targets
Lipids: Dietary Sources and Requirements

